Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
22 Februar 2024 - 3:19PM
Edgar (US Regulatory)
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of February 2024
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca prices a $5bn bond offering
22 February 2024 07:00 GMT
AstraZeneca prices a $5bn bond offering
AstraZeneca PLC ("AstraZeneca") announces that its wholly owned
subsidiary AstraZeneca Finance LLC, priced a four tranche global
bond offering totalling $5bn on 21 February 2024. The offering is
expected to close on 26 February 2024, subject to customary closing
conditions. The transaction, which is a global offering registered
with the US Securities and Exchange Commission ("SEC"), consists of
the following four tranches:
Notes issued by AstraZeneca Finance LLC and fully and
unconditionally guaranteed by AstraZeneca
● $1.25bn
of fixed rate notes with a coupon of 4.80%,
maturing 26 February 2027;
● $1.25bn
of fixed rate notes with a coupon of 4.85%,
maturing 26 February 2029;
● $1.00bn
of fixed rate notes with a coupon of 4.90%,
maturing 26 February 2031;
and
● $1.50bn
of fixed rate notes with a coupon of 5.00%,
maturing 26 February 2034.
AstraZeneca expects to use the net proceeds of the offering for
general corporate purposes, which may include the refinancing of
existing indebtedness.
Barclays Capital Inc., Citigroup Global Markets Inc., Deutsche
Bank Securities Inc. and J.P. Morgan Securities LLC acted as
joint book-running managers on the transaction. In
addition, and in line with our commitment to Inclusion &
Diversity, four inclusive and diverse firms acted as underwriters
on the transaction: Blaylock Van, LLC, Cabrera Capital Markets LLC,
C.L. King & Associates, Inc. and Stern Brothers &
Co.
The notes will be issued under AstraZeneca's effective shelf
registration statement on Form F-3, which AstraZeneca and
AstraZeneca Finance LLC filed with the SEC on 24 May 2021. The
offering is being made solely by means of the prospectus contained
within that shelf registration statement, along with a prospectus
supplement forming part of the effective registration statement,
which investors should read.
A copy of the prospectus supplement and accompanying prospectus
relating to the offering can be obtained by contacting Barclays
Capital Inc. by telephone at +1-888-603-5847; Citigroup Global
Markets Inc. by telephone at +1-800-831-9146; Deutsche Bank
Securities Inc. toll-free at +1-800-503-4611; or J.P. Morgan
Securities LLC collect at +1-212-834-4533. Readers may also
download these documents for free by visiting the Electronic Data
Gathering, Analysis, and Retrieval (EDGAR) system on the SEC
website at www.sec.gov.
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such jurisdiction.
The bond issuance does not impact AstraZeneca's financial guidance
for 2024.
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
22 February 2024
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Okt 2023 bis Okt 2024